Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function

National Osteoporosis Foundation National Kidney Foundation Kidney Disease Outcomes Quality Initiative Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial, JAMA, 280, 2077, 10.1001/jama.280.24.2077 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial, JAMA, 282, 1344, 10.1001/jama.282.14.1344 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis, Osteoporos Int., 11, 83, 10.1007/s001980050010 2004 2003 Bounameaux, 1983, Renal failure associated with intravenous diphosphonates, Lancet, 1, 471, 10.1016/S0140-6736(83)91465-4 Adami, 1996, Adverse effects of bisphosphonates. A comparative review, Drug Saf, 14, 158, 10.2165/00002018-199614030-00003 Hansen, 2003, Efficacy and tolerability of alendronate in veterans with renal insufficiency Lewiecki, 2002, Oral bisphosphonates for treatment of osteoporosis in elderly patients with impaired renal function Miller, 2004, OC46: Safety and efficacy of risedronate in patients with reduced renal function. A pooled analysis of 9 clinical trials Siris, 2004, Safety and efficacy of risedronate 30mg/day in patients with a reduced renal function Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Anderson, 2004, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial, JAMA, 291, 1701, 10.1001/jama.291.14.1701 Hernandez, 2003, Effects of raloxifene on bone metabolism and serum lipids in post-menopausal women on chronic hemodialysis, Kidney Int., 63, 2269, 10.1046/j.1523-1755.2003.00005.x Weisinger, 2003, Selective estrogen receptor modulators in chronic renal failure, Kidney Int Suppl., 85, S62, 10.1046/j.1523-1755.63.s85.15.x Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial, JAMA, 282, 637, 10.1001/jama.282.7.637 2001 Chesnut, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study, Am J Med, 109, 267, 10.1016/S0002-9343(00)00490-3 Follin, 2003, Current approaches to the prevention and treatment of postmenopausal osteoporosis, Am J Health Syst Pharm., 60, 883, 10.1093/ajhp/60.9.883 2002